<div id="readability-page-1"><p>Capital Group Private Client Services Inc. lessened its position in shares of  Amgen Inc. (NASDAQ:AMGN - Free Report) by 27.7% in the fourth quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 67,479 shares of the medical research company's stock after selling 25,906 shares during the period. Capital Group Private Client Services Inc.'s holdings in Amgen were worth $17,588,000 at the end of the most recent reporting period.</p><ul><li>MarketBeat Week in Review – 12/2 - 12/6</li></ul><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. Talbot Financial LLC increased its position in shares of  Amgen by 5.6% during the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares in the last quarter.  Asset Advisors Investment Management LLC raised its stake in  Amgen by 9.0% in the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after acquiring an additional 2,954 shares during the period.  Ascent Wealth Partners LLC increased its stake in shares of  Amgen by 0.7% in the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after purchasing an additional 64 shares in the last quarter.  Principal Financial Group Inc. boosted its holdings in  Amgen by 6.0% in the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after buying an additional 35,785 shares during the period.  Finally, ICICI Prudential Asset Management Co Ltd grew its stake in  Amgen by 242.2% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after buying an additional 16,985 shares in the last quarter. Institutional investors own  76.50% of the company's stock. </p><h2>Amgen Price Performance</h2><p>AMGN opened at $277.29 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock's 50 day simple moving average is $303.04 and its 200 day simple moving average is $294.22. The firm has a market cap of $149.09 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. </p><ul><li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li></ul><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.  As a group, analysts predict that  Amgen Inc. will post 20.62 earnings per share for the current year. </p><h2>Amgen Announces Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen's dividend payout ratio  is presently 126.09%. </p><h2>Insider Buying and Selling at Amgen</h2><ul><li>2 Generic Drug Stocks Ready to Surge in 2025</li></ul><p>In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. Insiders own  0.69% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>AMGN has been the subject of several recent research reports. Piper Sandler Companies  reiterated an &#34;overweight&#34; rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Citigroup  reissued a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America upped their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an &#34;underperform&#34; rating in a report on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, February 10th. Finally, Wells Fargo &amp; Company  reiterated an &#34;equal weight&#34; rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued  a buy rating and one  has issued  a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $314.91.</p><p><b>Check Out Our Latest Report on Amgen</b></p><h2>About Amgen</h2> (Free Report)<p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Amgen</li><li>Market Cap Calculator: How to Calculate Market Cap</li><li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li><li>How Investors Can Find the Best Cheap Dividend Stocks</li><li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li><li>How to Start Investing in Real Estate</li><li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li></ul><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Capital Group Private Client Services Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 27.7% in Q4, selling 25,906 shares, leaving it with 67,479 shares valued at $17.59 million. Other institutional investors also adjusted their positions, with Talbot Financial LLC increasing its stake by 5.6%. Amgen's stock opened at $277.29, with a market cap of $149.09 billion and a P/E ratio of 36.73. The company recently declared a quarterly dividend of $2.38 per share, with a yield of 3.43%.</p>

Capital Group Private Client Services Inc. Sells 25,906 Shares of Amgen Inc. (NASDAQ:AMGN)